Video

Dr Aimee Tharaldson on the Interest in Developing Orphan Drugs

Orphan medications are gaining a lot of focus from manufacturers, Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts, said at the Academy of Managed Care Pharmacy's 27th Annual Meeting & Expo in San Diego, April 7-10.

Orphan medications are gaining a lot of focus from manufacturers, Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts, said at the Academy of Managed Care Pharmacy's 27th Annual Meeting & Expo in San Diego, April 7-10.

These drugs treat populations of less than 200,000 patients, but manufacturers are given financial incentives to develop orphan medications and as a result in 2014, 75% of specialt drug approvals were for orphan drugs.

"These medications cost hundreds of thousands of dollars a year and oftetimes about 30% of orphan medications become blockbuster medications," Dr Tharaldson said.

Related Videos
Dr Duke Appiah
Shawn Griffin, MD, sitting for a video interview
Kathi Henson, MBA, sitting for a video interview
Mike Fazio, Navista, Cardinal Health
Dr Mingyang Song
Dr K. Vish Viswanath
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Dr Raymond Osarogiagbon
Dr Kimlin Tam Ashing
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo